Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Common Pathogenic Mechanisms Between Idiopathic Pulmonary Fibrosis and Lung Cancer.

Tzouvelekis A, Gomatou G, Bouros E, Trigidou R, Tzilas V, Bouros D.

Chest. 2019 May 22. pii: S0012-3692(19)31095-5. doi: 10.1016/j.chest.2019.04.114. [Epub ahead of print] Review.

PMID:
31125557
2.

Human pentraxin 2 protein treatment for IPF.

Tzouvelekis A, Tzilas V, Antoniou KM, Bouros D.

Lancet Respir Med. 2019 May 17. pii: S2213-2600(19)30173-0. doi: 10.1016/S2213-2600(19)30173-0. [Epub ahead of print] No abstract available.

PMID:
31122900
3.

Safety and Efficacy of Early and Long-Term Use of Pirfenidone in Idiopathic Pulmonary Fibrosis.

Tzilas V, Tzouvelekis A, Bouros D.

Respiration. 2019 Apr 4:1-3. doi: 10.1159/000497391. [Epub ahead of print] No abstract available.

PMID:
30947205
4.

Interstitial lung abnormalities: ignotum per ignotius.

Antoniou KM, Tzilas V, Vasarmidi E, Symvoulakis EK, Tzouvelekis A, Bouros D.

Lancet Respir Med. 2019 May;7(5):376-378. doi: 10.1016/S2213-2600(19)30052-9. Epub 2019 Mar 29. No abstract available.

PMID:
30935882
5.

Biologic Treatments in Interstitial Lung Diseases.

Karampitsakos T, Vraka A, Bouros D, Liossis SN, Tzouvelekis A.

Front Med (Lausanne). 2019 Mar 13;6:41. doi: 10.3389/fmed.2019.00041. eCollection 2019. Review.

6.

Measles Pneumonitis.

Schoini P, Karampitsakos T, Avdikou M, Athanasopoulou A, Tsoukalas G, Tzouvelekis A.

Adv Respir Med. 2019 Mar 4. doi: 10.5603/ARM.a2019.0010. [Epub ahead of print]

7.

Idiopathic interstitial pneumonia or idiopathic interstitial pneumonitis: what's in a name?

Kolilekas L, Costabel U, Tzouvelekis A, Tzilas V, Bouros D.

Eur Respir J. 2019 Feb 14;53(2). pii: 1800994. doi: 10.1183/13993003.00994-2018. Print 2019 Feb. No abstract available.

PMID:
30765482
8.

Vitamin D prevents experimental lung fibrosis and predicts survival in patients with idiopathic pulmonary fibrosis.

Tzilas V, Bouros E, Barbayianni I, Karampitsakos T, Kourtidou S, Ntassiou M, Ninou I, Aidinis V, Bouros D, Tzouvelekis A.

Pulm Pharmacol Ther. 2019 Apr;55:17-24. doi: 10.1016/j.pupt.2019.01.003. Epub 2019 Jan 16.

PMID:
30659895
9.

Coexistence of Tracheobronchopathia Osteochondroplastica and Sarcoidosis: Accidental Finding or Something More?

Chrysikos S, Karampitsakos T, Tzouvelekis A, Dimakou K.

J Bronchology Interv Pulmonol. 2019 Jan;26(1):e7-e8. doi: 10.1097/LBR.0000000000000521. No abstract available.

PMID:
30562285
10.

Diagnostic guidelines for IPF: when art meets science.

Bouros D, Tzilas V, Tzouvelekis A.

Lancet Respir Med. 2018 Nov;6(11):812-814. doi: 10.1016/S2213-2600(18)30430-2. No abstract available.

PMID:
30484427
11.

Pirfenidone in the kaleidoscope: reflecting mechanisms through different angles.

Tzouvelekis A, Wolters PJ.

Eur Respir J. 2018 Nov 22;52(5). pii: 1802046. doi: 10.1183/13993003.02046-2018. Print 2018 Nov. No abstract available.

PMID:
30467176
12.

Lung function changes after chemoradiation therapy in patients with lung cancer treated by three usual platinum combinations.

Mihailidis V, Anevlavis S, Karpathiou G, Kouliatsis G, Tzouvelekis A, Zarogoulidis P, Ntolios P, Steiropoulos P, Bouros D, Froudarakis ME.

J Thorac Dis. 2018 Sep;10(9):5435-5442. doi: 10.21037/jtd.2018.08.139.

13.

Endobronchial metastasis from renal cell carcinoma as a reason for recurrent pulmonary infections.

Chrysikos S, Karampitsakos T, Tzouvelekis A, Dimakou K.

Adv Respir Med. 2018;86(5):245-248. doi: 10.5603/ARM.2018.0039.

14.

Bleomycin Revisited: A Direct Comparison of the Intratracheal Micro-Spraying and the Oropharyngeal Aspiration Routes of Bleomycin Administration in Mice.

Barbayianni I, Ninou I, Tzouvelekis A, Aidinis V.

Front Med (Lausanne). 2018 Sep 24;5:269. doi: 10.3389/fmed.2018.00269. eCollection 2018.

15.

Association of Asthma and Allergic Rhinitis With Sleep-Disordered Breathing in Childhood.

Perikleous E, Steiropoulos P, Nena E, Iordanidou M, Tzouvelekis A, Chatzimichael A, Paraskakis E.

Front Pediatr. 2018 Sep 11;6:250. doi: 10.3389/fped.2018.00250. eCollection 2018.

16.

Early Career Members at the ERS Lung Science Conference: cell-matrix interactions in lung disease and regeneration: Early career forum.

Almendros I, Alsafadi HN, Bölükbas D, Collins JJP, Duch P, Garrido-Martin EM, Kahn N, Karampitsakos T, Mahmutovic Persson I, Tzouvelekis A, Uhl FE, Bartel S.

Breathe (Sheff). 2018 Jun;14(2):e78-e83. doi: 10.1183/20734735.016818.

17.

The Management of Patients With Idiopathic Pulmonary Fibrosis.

Spagnolo P, Tzouvelekis A, Bonella F.

Front Med (Lausanne). 2018 Jul 2;5:148. doi: 10.3389/fmed.2018.00148. eCollection 2018. Review.

18.

Metformin in Idiopathic Pulmonary Fibrosis "Seeking the Holy-Grail through Drug-Repositioning".

Tzouvelekis A, Tzilas V, Dassiou M, Bouros D.

Respiration. 2018;96(4):305-307. doi: 10.1159/000490917. Epub 2018 Jul 13. No abstract available.

PMID:
30007987
19.

Prognosis of Interstitial Lung Disease Associated with Anti-Aminoacyl-tRNA Synthetase Antibodies: Look in the Middle.

Tzilas V, Tzouvelekis A, Bouros E, Bouros D.

Respiration. 2018;96(3):207-209. doi: 10.1159/000489936. Epub 2018 Jun 19. No abstract available.

PMID:
29920503
20.

DNA Methylation in Pediatric Obstructive Sleep Apnea: An Overview of Preliminary Findings.

Perikleous E, Steiropoulos P, Tzouvelekis A, Nena E, Koffa M, Paraskakis E.

Front Pediatr. 2018 May 29;6:154. doi: 10.3389/fped.2018.00154. eCollection 2018. Review.

21.

Mesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis.

Tzouvelekis A, Toonkel R, Karampitsakos T, Medapalli K, Ninou I, Aidinis V, Bouros D, Glassberg MK.

Front Med (Lausanne). 2018 May 15;5:142. doi: 10.3389/fmed.2018.00142. eCollection 2018. Review.

22.

Cardiovascular Risk Assessment in a Cohort of Newly Diagnosed Patients with Obstructive Sleep Apnea Syndrome.

Archontogeorgis K, Voulgaris A, Nena E, Strempela M, Karailidou P, Tzouvelekis A, Mouemin T, Xanthoudaki M, Steiropoulos S, Froudarakis ME, Steiropoulos P.

Cardiol Res Pract. 2018 Mar 8;2018:6572785. doi: 10.1155/2018/6572785. eCollection 2018.

23.

Nintedanib in Severe Idiopathic Pulmonary Fibrosis: Effectiveness through Compassion.

Tzouvelekis A, Bouros D.

Respiration. 2018;95(6):401-402. doi: 10.1159/000488647. Epub 2018 Apr 25. No abstract available.

PMID:
29694983
24.

S100A12 as a marker of worse cardiac output and mortality in pulmonary hypertension.

Tzouvelekis A, Herazo-Maya JD, Ryu C, Chu JH, Zhang Y, Gibson KF, Adonteng-Boateng PK, Li Q, Pan H, Cherry B, Ahmad F, Ford HJ, Herzog EL, Kaminski N, Fares WH.

Respirology. 2018 Aug;23(8):771-779. doi: 10.1111/resp.13302. Epub 2018 Apr 2.

25.

Pulmonary hypertension in patients with interstitial lung disease.

Karampitsakos T, Tzouvelekis A, Chrysikos S, Bouros D, Tsangaris I, Fares WH.

Pulm Pharmacol Ther. 2018 Jun;50:38-46. doi: 10.1016/j.pupt.2018.03.002. Epub 2018 Mar 29. Review.

PMID:
29605286
26.

A Rare Case of Primary Intrapulmonary Neurilemmoma Diagnosed in a 43-Year-Old Asymptomatic Man with a Well-defined Intrapulmonary Mass.

Chrysikos S, Kaponi M, Triantafillidou C, Karampitsakos T, Tzouvelekis A, Anyfanti M, Marossis K, Konstantinou M, Tringidou R, Bouros D, Dimakou K.

Front Oncol. 2018 Jan 30;8:11. doi: 10.3389/fonc.2018.00011. eCollection 2018.

27.

Longitudinal outcomes of patients enrolled in a phase Ib clinical trial of the adipose-derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis.

Ntolios P, Manoloudi E, Tzouvelekis A, Bouros E, Steiropoulos P, Anevlavis S, Bouros D, Froudarakis ME.

Clin Respir J. 2018 Jun;12(6):2084-2089. doi: 10.1111/crj.12777. Epub 2018 Mar 12.

PMID:
29412521
28.

Metabolic Disorders in Chronic Lung Diseases.

Papaioannou O, Karampitsakos T, Barbayianni I, Chrysikos S, Xylourgidis N, Tzilas V, Bouros D, Aidinis V, Tzouvelekis A.

Front Med (Lausanne). 2018 Jan 18;4:246. doi: 10.3389/fmed.2017.00246. eCollection 2017. Review.

29.

Insulin Sensitivity and Insulin Resistance in Non-Diabetic Middle-Aged Patients with Obstructive Sleep Apnoea Syndrome.

Archontogeorgis K, Papanas N, Nena E, Tzouvelekis A, Tsigalou C, Voulgaris A, Xanthoudaki M, Mouemin T, Froudarakis M, Steiropoulos P.

Open Cardiovasc Med J. 2017 Dec 29;11:159-168. doi: 10.2174/1874192401711010159. eCollection 2017.

30.

Corrigendum: Longitudinal "Real-World" Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece.

Tzouvelekis A, Karampitsakos T, Ntolios P, Tzilas V, Bouros E, Markozannes E, Malliou I, Anagnostopoulos A, Granitsas A, Steiropoulos P, Dimakou K, Chrysikos S, Koulouris N, Bouros D.

Front Med (Lausanne). 2018 Jan 24;4:257. doi: 10.3389/fmed.2017.00257. eCollection 2017.

31.

Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: A real-life observational study in Greece.

Tzouvelekis A, Karampitsakos T, Kontou M, Granitsas A, Malliou I, Anagnostopoulos A, Ntolios P, Tzilas V, Bouros E, Steiropoulos P, Chrysikos S, Dimakou K, Koulouris N, Bouros D.

Pulm Pharmacol Ther. 2018 Apr;49:61-66. doi: 10.1016/j.pupt.2018.01.006. Epub 2018 Jan 31.

PMID:
29366978
32.

Patients with IPF and lung cancer: diagnosis and management.

Tzouvelekis A, Spagnolo P, Bonella F, Vancheri C, Tzilas V, Crestani B, Kreuter M, Bouros D.

Lancet Respir Med. 2018 Feb;6(2):86-88. doi: 10.1016/S2213-2600(17)30478-2. Epub 2017 Dec 11. Review. No abstract available.

PMID:
29241977
33.

Longitudinal "Real-World" Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece.

Tzouvelekis A, Karampitsakos T, Ntolios P, Tzilas V, Bouros E, Markozannes E, Malliou I, Anagnostopoulos A, Granitsas A, Steiropoulos P, Dimakou K, Chrysikos S, Koulouris N, Bouros D.

Front Med (Lausanne). 2017 Nov 29;4:213. doi: 10.3389/fmed.2017.00213. eCollection 2017. Erratum in: Front Med (Lausanne). 2018 Jan 24;4:257.

34.

Thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function.

Yu G, Tzouvelekis A, Wang R, Herazo-Maya JD, Ibarra GH, Srivastava A, de Castro JPW, DeIuliis G, Ahangari F, Woolard T, Aurelien N, Arrojo E Drigo R, Gan Y, Graham M, Liu X, Homer RJ, Scanlan TS, Mannam P, Lee PJ, Herzog EL, Bianco AC, Kaminski N.

Nat Med. 2018 Jan;24(1):39-49. doi: 10.1038/nm.4447. Epub 2017 Dec 4.

35.

Taking a giant step in the diagnosis of idiopathic pulmonary fibrosis.

Tzilas V, Valeyre D, Tzouvelekis A, Bouros D.

Lancet Respir Med. 2018 Feb;6(2):82-84. doi: 10.1016/S2213-2600(17)30443-5. Epub 2017 Nov 15. No abstract available.

PMID:
29154105
36.

Metsovo Lung: A Story of Episteme, Techne, and Phronesis.

Tzilas V, Tzouvelekis A, Bouros D.

Respiration. 2017;94(6):491-492. doi: 10.1159/000481291. Epub 2017 Oct 13. No abstract available.

37.

Diagnosis of Idiopathic Pulmonary Fibrosis "Pragmatic Challenges in Clinical Practice".

Tzilas V, Tzouvelekis A, Chrysikos S, Papiris S, Bouros D.

Front Med (Lausanne). 2017 Sep 20;4:151. doi: 10.3389/fmed.2017.00151. eCollection 2017. Review.

38.

Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study.

Herazo-Maya JD, Sun J, Molyneaux PL, Li Q, Villalba JA, Tzouvelekis A, Lynn H, Juan-Guardela BM, Risquez C, Osorio JC, Yan X, Michel G, Aurelien N, Lindell KO, Klesen MJ, Moffatt MF, Cookson WO, Zhang Y, Garcia JGN, Noth I, Prasse A, Bar-Joseph Z, Gibson KF, Zhao H, Herzog EL, Rosas IO, Maher TM, Kaminski N.

Lancet Respir Med. 2017 Nov;5(11):857-868. doi: 10.1016/S2213-2600(17)30349-1. Epub 2017 Sep 21.

39.

Pirfenidone in Idiopathic Pulmonary Fibrosis "RECAP-itulating Safety into the Real World".

Tzouvelekis A, Bouros E, Tzilas V, Bouros D.

Respiration. 2017;94(5):405-407. doi: 10.1159/000480299. Epub 2017 Sep 5. No abstract available.

40.

Chronic Kidney Disease and Idiopathic Pulmonary Fibrosis: Thinking Outside the Box in Disease Management and Prognostication.

Tzouvelekis A, Bouros E, Bouros D.

Respiration. 2017;94(4):334-335. doi: 10.1159/000480093. Epub 2017 Aug 26. No abstract available.

41.

Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study.

Tzouvelekis A, Ntolios P, Karampitsakos T, Tzilas V, Anevlavis S, Bouros E, Steiropoulos P, Koulouris N, Stratakos G, Froudarakis M, Bouros D.

Pulm Pharmacol Ther. 2017 Oct;46:48-53. doi: 10.1016/j.pupt.2017.08.011. Epub 2017 Aug 24.

PMID:
28843616
42.

Exploring Animal Models That Resemble Idiopathic Pulmonary Fibrosis.

Tashiro J, Rubio GA, Limper AH, Williams K, Elliot SJ, Ninou I, Aidinis V, Tzouvelekis A, Glassberg MK.

Front Med (Lausanne). 2017 Jul 28;4:118. doi: 10.3389/fmed.2017.00118. eCollection 2017. Review.

43.

Extracellular Mitochondrial DNA Is Generated by Fibroblasts and Predicts Death in Idiopathic Pulmonary Fibrosis.

Ryu C, Sun H, Gulati M, Herazo-Maya JD, Chen Y, Osafo-Addo A, Brandsdorfer C, Winkler J, Blaul C, Faunce J, Pan H, Woolard T, Tzouvelekis A, Antin-Ozerkis DE, Puchalski JT, Slade M, Gonzalez AL, Bogenhagen DF, Kirillov V, Feghali-Bostwick C, Gibson K, Lindell K, Herzog RI, Dela Cruz CS, Mehal W, Kaminski N, Herzog EL, Trujillo G.

Am J Respir Crit Care Med. 2017 Dec 15;196(12):1571-1581. doi: 10.1164/rccm.201612-2480OC.

44.

Dissecting Survival Pathways in Lung Cancer, Fibrosis and Emphysema: "The Four Horses of the Apocalypse".

Tzouvelekis A, Tzilas V, Papiris S, Bouros D.

Respiration. 2017;94(3):239-241. doi: 10.1159/000478910. Epub 2017 Jul 19. No abstract available.

45.

Biomarkers in Idiopathic Pulmonary Fibrosis: A RAGE-ing Bull in the Arena.

Tzouvelekis A, Bouros D, Aidinis V.

Ann Am Thorac Soc. 2017 May;14(5):613-614. doi: 10.1513/AnnalsATS.201701-024ED. No abstract available.

PMID:
28459629
46.

Guidelines for Idiopathic Pulmonary Fibrosis: Everything Flows.

Tzilas V, Bouros E, Tzouvelekis A, Bouros D.

Respiration. 2017;93(6):401-403. doi: 10.1159/000473884. Epub 2017 Apr 27. No abstract available.

47.

Lung cancer in patients with idiopathic pulmonary fibrosis.

Karampitsakos T, Tzilas V, Tringidou R, Steiropoulos P, Aidinis V, Papiris SA, Bouros D, Tzouvelekis A.

Pulm Pharmacol Ther. 2017 Aug;45:1-10. doi: 10.1016/j.pupt.2017.03.016. Epub 2017 Apr 1. Review.

PMID:
28377145
48.

Extracellular matrix remodeling in idiopathic pulmonary fibrosis. It is the 'bed' that counts and not 'the sleepers'.

Tomos IP, Tzouvelekis A, Aidinis V, Manali ED, Bouros E, Bouros D, Papiris SA.

Expert Rev Respir Med. 2017 Apr;11(4):299-309. doi: 10.1080/17476348.2017.1300533. Epub 2017 Mar 8. Review.

PMID:
28274188
49.

Diagnostic and prognostic challenges in Idiopathic Pulmonary Fibrosis: A patient's "Q and A" approach.

Tzouvelekis A, Tzilas V, Papiris S, Aidinis V, Bouros D.

Pulm Pharmacol Ther. 2017 Feb;42:21-24. doi: 10.1016/j.pupt.2016.12.002. Epub 2016 Dec 12. Review.

PMID:
27979760
50.

Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis.

Tzouvelekis A, Herazo-Maya JD, Slade M, Chu JH, Deiuliis G, Ryu C, Li Q, Sakamoto K, Ibarra G, Pan H, Gulati M, Antin-Ozerkis D, Herzog EL, Kaminski N.

Respirology. 2017 Apr;22(3):486-493. doi: 10.1111/resp.12920. Epub 2016 Oct 19.

Supplemental Content

Loading ...
Support Center